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Abstract
The pathogenic fungus Cryptococcus neoformans exhibits morphological changes in cell
size during lung infection, producing both typical size 5 to 7 μm cells and large titan cells
(> 10 μm and up to 100 μm). We found and optimized in vitro conditions that produce titan
cells in order to identify the ancestry of titan cells, the environmental determinants, and the
key gene regulators of titan cell formation. Titan cells generated in vitro harbor the main
characteristics of titan cells produced in vivo including their large cell size (>10 μm), poly-
ploidy with a single nucleus, large vacuole, dense capsule, and thick cell wall. Here we show
titan cells derived from the enlargement of progenitor cells in the population independent of
yeast growth rate. Change in the incubation medium, hypoxia, nutrient starvation and low
pH were the main factors that trigger titan cell formation, while quorum sensing factors like
the initial inoculum concentration, pantothenic acid, and the quorum sensing peptide Qsp1p
also impacted titan cell formation. Inhibition of ergosterol, protein and nucleic acid biosyn-
thesis altered titan cell formation, as did serum, phospholipids and anti-capsular antibodies
in our settings. We explored genetic factors important for titan cell formation using three
approaches. Using H99-derivative strains with natural genetic differences, we showed that
titan cell formation was dependent on LMP1 and SGF29 genes. By screening a gene dele-
tion collection, we also confirmed that GPR4/5-RIM101, and CAC1 genes were required to
generate titan cells and that the PKR1, TSP2, USV101 genes negatively regulated titan cell
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formation. Furthermore, analysis of spontaneous Pkr1 loss-of-function clinical isolates con-
firmed the important role of the Pkr1 protein as a negative regulator of titan cell formation.
Through development of a standardized and robust in vitro assay, our results provide new
insights into titan cell biogenesis with the identification of multiple important factors/
pathways.
Author summary
Cryptococcus neoformans is a yeast that is capable of morphological change upon interac-
tion with the host. Particularly, in the lungs of infected mice, a subpopulation of yeast
enlarges, producing cells up to 100 μm in cell body diameter–referred to as titan cells.
Along with their large size, the titan cells have other unique characteristics such as thick-
ened cell wall, dense capsule, polyploidization, large vacuole with peripheral nucleus and
cellular organelles. The generation of a large number of such cells outside the lungs of
mice has been described but was not reproducible nor standardized. Here we report stan-
dardized, reproducible, robust conditions for generation of titan cells and explored the
environmental and genetic factors underlying the genesis of these cells. We showed that
titan cells were generated upon stresses such as change in the incubation medium, nutri-
ent deprivation, hypoxia and low pH. Using collections of well characterized reference
strains and clinical isolates, we validated with our model that the cAMP/PKA/Rim101
pathway is a major genetic determinant of titan cell formation. This study opens the way
for a more comprehensive picture of the ontology of morphological changes in Cryptococ-
cus neoformans and its impact on pathobiology of this deadly pathogen.
Introduction
The ubiquitous environmental yeast Cryptococcus neoformans is a basidiomycetous yeast that
has been estimated to cause over 200,000 new cases of meningoencephalitis with greater than
180,000 deaths per year worldwide [1], occurring mostly in immunocompromised individuals
with acquired immunodeficiency syndrome (AIDS) [2]. The natural history of most of the
cases of this invasive fungal infection proceeds through 3 stages: (i) primary infection via inha-
lation of desiccated yeasts or basidiospores, with development of sub-clinical pneumonia and
spontaneous resolution via granuloma formation; (ii) latency of dormant yeast cells, as dem-
onstrated epidemiologically [3] and biologically [4] and (iii) reactivation and dissemination
upon immunosuppression, with meningoencephalitis as the most severe clinical presentation
of disease [5]. From the environment to interactions with hosts, the yeasts experience drastic
changes that reflect a capacity to rapidly adapt and survive in host tissues and cause disease
[4,6–9]. In hosts, C. neoformans is exposed to various stresses including high temperature,
nutrient deprivation, low pH, hypoxia and high levels of free radicals [10].
In response to the host environment, morphological changes are required to survive and
cause disease [11]. Specifically, C. neoformans alters its morphology and produces enlarged
cells referred to as giant or “titan cells” [12,13]. This phenomenon has been observed in animal
and insect models of cryptococcosis, as well as in human lung and brain infections [12–16].
Titan cells have increased cell body size, ranging from 10 μm up to 100 μm in diameter
[12,13,17–21] as compared to the 5–7 μm size of typical cells. Studies exploring titan cell biol-
ogy have revealed that these are: (i) uninucleate polyploid cells [12,13,20]; (ii) possess a large
In vitro titan cell generation in Cryptococcus neoformans
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006982 May 18, 2018 2 / 38
(Poste d’ accueil APHP/CNRS/Institut Pasteur).
http://recherche.aphp.fr/candidatures-internes/ KN
grant funding National Institutes of Health, National
Institute of Allergy and Infectious Diseases (NIAID)
grant R01AI080275. https://www.niaid.nih.gov AC
is supported in part by 5R01HL059842,
5R01AI033774, 5R37AI033142, and
5R01AI052733. https://www.niaid.nih.gov CAD
and CAC were supported by National Institute of
Allergy and Infectious Diseases, National Institutes
of Health, Department of Health and Human
Services grant number U19AI110818. https://
www.niaid.nih.gov The funders had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
single vacuole; (iii) are surrounded by a thick cell wall [22]; and (iv) have a dense and highly
crosslinked capsule [13,17,22]. Titan cells also exhibit increased resistance to various stresses
including phagocytosis [21], oxidative and nitrosative stress [20,21], and resistance to the anti-
fungal drug fluconazole [20]. Importantly, titan cell production also enhances dissemination,
survival and virulence in a mouse model of infection [19]. Titan cell formation is known to be
regulated by the G-protein coupled receptors Gpr5 and Ste3a, that signal through the Gα sub-
unit protein Gpa1 to trigger the cyclic adenosine monophosphate / protein kinase A (cAMP/
PKA) signaling pathway [15,20,23–26]. The cAMP/PKA pathway is critical for regulation of
other virulence factors in C. neoformans, including capsule formation [23,24], notably through
its action on the ubiquitin-proteasome pathway [27]. Pka1 is known to be negatively regulated
by the protein Pkr1, and pkr1Δmutant strains exhibit enlarged capsule [23]. Further studies
show that titan cells formation is increased by high PKA1 expression or low Pkr1 activity and
is decreased by low PKA1 expression [6]. Downstream of the PKA pathway, Rim101, a major
transcription factor that again controls production of many virulence factors, is also necessary
for titan cell production [18].
To date, studies of titan cell formation have been hindered by an inability to consistently
and reproducibly generate large quantities of titan cells in vitro. Although several methods
have been reported for inducing large cells in vitro, there have been persistent problems in eas-
ily and consistently implementing these protocols across laboratories [17], presumably because
the variables that contribute to titan cell inducing conditions are not well understood.
In this study, we identified robust in vitro conditions that generate enlarged cells with many
of the in vivo titan cell characteristics and used this protocol to explore environmental and genetic
factors involved in titan cell formation. The genetic determinants of titan cell formation have
been investigated through a genotype-phenotype correlation study in H99-derivative laboratory
reference strains, through analysis of deletion and complementation in reference strains, and
analysis of genetic defects in clinical isolates using whole genome data and complementation.
Results
Titan cells generated in vitro had similar characteristics to in vivo titan cells
While growth in minimal medium using standard growth conditions had no effect on cell size,
we identified growth conditions that stimulated the production of enlarged yeast cells and
optimized this experimental protocol, referred to as our in vitro protocol, using the reference
strain H99O (S1 Fig). Observation of these in vitro-generated large cells by microscopy shows
many characteristics of titan cells including increased cell body size (diameter>10 μm), refrac-
tive cell wall, large central vacuole, and peripheral cell cytoplasm distribution, similar to in vivo
titan cells (Fig 1A). Our in vitro protocol proved to be reproducible with H99O reference
strains generating titan cells in three different laboratories throughout the world, although
some variability in the overall proportion of titan cells generated was observed (Fig 1B). Specif-
ically, the proportion of titan cells was 39.4% [interquartile range (IQR), [34.1–40.7] in Lab 1,
21.0% [12.5–26.8] in Lab 2 and 29.9% [23.1–48.5] in Lab 3. The distribution of yeast cell body
size from the in vitro protocol varied from 3.7 to 16.3 μm (median 10.2 [8.5–11.5]), whereas in
vivo it varies from 3.6 to 41.8 μm (median 14.8 [11.2–18.45]) with 84% of the yeasts classified
as titan cells (Fig 1C).
Titan cells differ from typical cells in various characteristics including capsule size budding
rate, DNA content, cell wall and capsule structure, and the extent of melanization
[12,13,20,22]. Comparison of in vitro titan cells (TC) to typical cells (tC) showed a significant
increase in capsule size (median 4.8 μm in titan cells vs 2.7 μm in typical cells, p<0.001) similar
to that observed in vivo (median 10.5 μm in titan cells vs 8.0 in typical cells, p<0.001, Fig 1D).
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The capsule thickness of in vivo titan cells was increased compared to the in vitro titan cells.
The budding rate of in vitro titan cells was also significantly increased (median 82.5 m per
bud) compared to typical cells (median 89.0 m per bud) (p = 0.018), whereas it was similar for
titan and typical cells produced in vivo. Interestingly, overall budding rate was faster in vivo
than in vitro cells (68 and 89 m per bud, p<0.001)). The budding rate of both in vivo and in
vitro tutan cells and typical cells were faster than cells grown in stationary phase (111.5 and
124.5 m per bud in minimal medium (MM) and YPD, respectively) (Fig 1E, S1 Movie, S2
Movie). To analyze DNA content, yeasts obtained at the end of the in vitro protocol were
stained with propidium iodide (PI) and DNA content of titan (TC, FSC/SSChigh) and typical
(tC, FSC/SSClow) cells was compared to haploid (H99O) and diploid (AD7-77) strains grown
in Sabouraud medium. DNA content was higher in titan (FSC/SSChigh) than typical (FSC/
SSSlow) cells (Fig 1F), with an increase in the proportion of polyploid cells in the titan cell pop-
ulation as observed by a PI fluorescence greater than the diploid control strain (red arrow, Fig
1G). In contrast, the typical cells had the same PI fluorescence pattern as the haploid H99O
cells. Similarly, a reverse gating strategy based on PI intensity shows yeasts with the highest PI
intensity were large titan cells (red arrows, S2 Fig).
Calcofluor white (CFW) staining was used to analyze cell wall chitin content. After multi-
spectral imaging flow cytometry—gating on the titan and typical cell populations under both
in vitro and in vivo conditions (Fig 2A and 2B)—CFW fluorescence intensity (Fig 2C and 2D)
showed significantly increased fluorescence of titan cells compared to typical cells in vitro
(322539 ± 3072 vs 123062 ± 20727, p<0.0001, Fig 2C) and in vivo (144909 ± 38487 vs 27622 ±
7412, p<0.0001, Fig 2D). Cell sorting based on CFW staining and fluorescence microscopy
allowed us to validate that cells exhibiting the higher CFW intensity were titan cells (FSC/
SSChigh, S3B Fig). Measurements of chitin content using fluorescence microscopy also showed
significant increases in titan cells compared to typical cells (fluorescence intensity/pixel/cell
87.9 [71.7–107.7] vs 66.5 [51.7–79.4], respectively, p<0.0001, S4A Fig). Chitin levels were also
assessed by N-acetylglucosamine (Gluc-NAc) content. Gluc-NAc levels were higher in titan
cells (156.3 mM/g [153.7–203.7]) than typical cells (97.7 [87.2–119.3]), (p<0.001, S4B Fig).
Furthermore, titan cells exhibited pronounced melanization (S4C Fig), as measured by black-
ness on the pictures (S4D Fig), compared to typical cells (S4D Fig), with a median of the
(max—mean grey intensity per pixel) of 20065 [18785–21887] in titan vs 13067 [9660–15998]
in typical cells (p<0.0001).
Finally, capsule structure was also investigated based on the binding pattern of monoclonal
antibodies specific for capsular polysaccharides [28] using multispectral imaging flow
Fig 1. Titan cells generated in vitro harbor the typical phenotype of titan cells produced in vivo. (A) Specific morphology of titan cells
(TC, white arrow) in vitro (left panel) and in vivo (right panel) was observed: enlarged capsule (a), increased cell body size> 10 μm (b),
thickened cell wall, large central vacuole, and peripheral cell cytoplasm distribution) while the size of typical cells (tC, white arrow) is
<10 μm. (B) Titan cells were reproducibly generated in lab 1 using H99O and in two independent laboratories (lab 2 and lab 3) using
their local H99O strain. Cell size was measured manually or by using the Icy software on pictures taken in bright field. Each dot
represents an independent experiment (median [interquartile range, IQR] are presented); (C) Cell body size is increased in vivo
compared to in vitro. Dots represent individual cells, and boxes median and IQR for 230 cells each (p<0.0001) (D) Capsule size
measured after India ink staining was significantly larger in titan cells (TC) than in typical cells (tC) both in vitro and in vivo, in general,
the capsule was larger in vivo independently of the cell size (p<0.0001). Dots represent individual cells, and boxes median and IQR for
250 cells each (p<0.001); (E). The budding rate of titan cells was lower compared to that of typical cells upon incubation in minimal
medium (MM) after titan cells generation in vitro (p = 0.018) but not in vivo. In vivo, budding rate of titan cells (TC) and typical cells
(tC) were equivalent and increased as compared to in vitro titan cells and typical cells and controls (p<0.001).(F) The yeasts recovered
at step 4 of the protocol and analyzed by dot plots (FSC/SSC) using flow cytometry included two populations FSC/SSChigh and FSC/
SSClow representing titan cells (TC) and typical cells (tC), respectively; (G) DNA content analysis after propidium iodide (PI) staining
showed that the titan cells (FSC/SSChigh) population harbored increased PI fluorescence intensity from 2C to>4C (red arrow) as
compared to the diploid control (AD7-77 cultured in Sabouraud agar) while the typical cells (FSC/SSClow) population harbored a PI
intensity comparable to the haploid control (H99O cultured in Sabouraud agar).
https://doi.org/10.1371/journal.ppat.1006982.g001
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cytometry (Fig 2E and 2F, S5A Fig) and immunofluorescence (S5B Fig). Based on the fluores-
cence pattern of the 2D10 antibody [29], the algorithm modulation and bright details intensity
R7 allowed us to discriminate the distribution of the capsule staining in titan (TC) and typical
(tC) cells and showed with almost no overlap between both population in vitro (Fig 2E) and in
vivo populations (Fig 2F). Variability of staining was observed for E1 (IgG1) and 13F1 (IgM)
antibodies (S5A Fig). No pronounced differences between the capsule structures of titan and
typical cells was observed visually during immunofluorescence staining (S5B Fig).
Titan cells develop from older cells and produce typical sized daughter cells
To examine temporal changes in cell size induced by our protocol, we measured yeast cell sizes
at 0, 4, 8, 16, 24 and 120 h using automated analysis. This automated analysis correlated with
manual size measurements (Interclass correlation = 0.99) and titan/typical cell classification
(Kappa test = 0.81±0.07). The median cell size increased during the first 24 h of incubation,
starting at 5.7 μm [5.4–6.0] and increasing to 9.7 μm [8.4–11.0] (Fig 3A). The first titan cells
were observed at 8 h with a progressive increase in the proportion of titan cells overtime,
reaching a plateau by 24 h (Fig 3B).
Temporal changes in cell morphology were determined using light microscopy and live cell
imaging. Cells with the large vacuole characteristic of titan cells appeared between 4 and 8 h
(Fig 3C, white arrow). Live cell imaging over 12 h (Fig 3D, S3 Movie) showed that: (i) titan
cells swelled from the progenitor typical sized cells and (ii) titan cells divided to produce typi-
cal sized daughter cells. CFW staining is known to transfer only partially to daughter cells
upon division resulting in lower fluorescence in daughter cells while remaining at a high level
in mother cells [4,30]. Pulsed CFW staining was used to further monitor the ancestry of titan
and typical cell populations over time using flow cytometry (Fig 3E). The initial CFW stained
population (0 h) consisted of typical cells (FSClow) with high CFW fluorescence intensity
(black density lines). At 24 h, two populations were observed. The titan cell population
(FSChigh) had high CFW fluorescence intensity (black arrow), indicating these cells were gen-
erated by the swelling of typical sized cells in the original culture. The second population con-
sisted of typical cells (white arrow, FSClow) with low calcofluor fluorescence, consistent with
newly formed daughter cells (Fig 3E, right panel). Combined, these data show that the titan
cells derived from the initial inoculated cells and daughter cells are typical sized.
Generation of titan cells in vitro was influenced by environmental
conditions
We tested several parameters affecting steps 2 and 3 of our protocol described in S1 Fig and
identified parameters that significantly influenced titan cell generation, as measured by cell
size distribution and proportion of titan cells. The first parameter we tested was the growth
medium and transition between different growth media (Fig 4A). Initial culture in YPD (step
2) then transfer to MM (step 3) resulted in the highest median cell size at 9.1 μm [6.9–11.1].
Initial culture MM followed by transfer to MM produced fewer titan cells, 25.5% (118/463) vs
39.5% (182/461), although the titan cells tended to be larger with cell body diameters over
Fig 2. Titan cells harbor an increased chitin content and capsule structure in vitro and in vivo using multispectral
imaging flow cytometry. (A) Titan cells (TC) and typical cells (tC) were selected in the corresponding gates based on
the Area/Diameter dot plot. (B) Titan cells in vivo are bigger than that produced in vitro. The chitin content based on
calcofluor white (CFW) fluorescence intensity showed significantly increased fluorescence of titan cells compared to
typical cells in vitro (C) and in vivo (D). Based on the fluorescence pattern of the 2D10 anti-capsular monoclonal
antibody, the algorithms "modulation" and "bright details intensity R7" allowed to discriminate the capsule structure of
titan cells and typical cells with almost no overlap between both population in vitro (E) and in vivo (F).
https://doi.org/10.1371/journal.ppat.1006982.g002
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Fig 3. Dynamics of titan cells generation in vitro. (A) Cell body size was measured from samples of H99O culture (step 3 of the protocol)
withdrawn at specific times (H0 to H120) using pictures taken in bright field and measured with the ICY software (mean number of yeasts
counted ± SD = 219 ± 67, representative of three experiments). Cell size increased starting at H8 with some cells reaching the threshold of
10 μm (grey dashed line). Each dot represents a single cell and the bars represent median and IQR; (B) Titan cells generation started
between H8 and H12 and reached a plateau at H24. Each dot represents the proportion of titan cells in the corresponding sample (3
independent experiments); (C) Pictures (x400 magnification) taken overtime showing the progressive increase in cell body size and the
appearance of a vacuole typical of titan cells in a large cell at H8 (white arrow) (scale bar 10 μm); (D) Time lapse imaging of titan cells
generation over 12 h showing that titan cells swelled progressively from a small cell and produced daughter cells after having increased
their size. (E) Cells stained with calcofluor (CFW) at 0.1 μg/mL prior to incubation using our protocol. CFW fluorescent intensity is
analyzed by flow cytometry in the initial (H0) and the resulting FSC/SSChigh (titan cells) and FSC/SSClow (typical cells) observed at H24.
The initial (H0) (green line) and the H24 FSC/SSChigh (blue line) populations harbored a high CFW fluorescence suggesting that they are
mother cells, with a higher fluorescence for the FSC/SSChigh, while two populations of high and low (black star) CFW fluorescence
intensity were observed for the H24 FSC/SSClow cells (Left panel). The right panel shows the size (FSC) and CFW fluorescence intensity of
the yeast populations at H0 (black content lines) and H24 (yellow content lines). The initial population (CFWhigh/FSClow) evolved in two
populations, one corresponding to daughter cells (typical cells, CFWlow/FSClow, white arrow), and the other one corresponding to titan
cells (CFWhigh/FSChigh, black arrow).
https://doi.org/10.1371/journal.ppat.1006982.g003
Fig 4. Titan cells generation in vitro is impacted by various environmental conditions. (A) The sequence of media used at steps 2 and 3 of the protocol was crucial
for titan cells generation: yeasts cultured in Yeast Peptone Dextrose (YPD) and transferred to minimal medium (MM) produced significantly more titan cells (cells
>10μm, dotted grey line) than yeasts cultured in MM or YPD and transferred in MM or YPD, respectively; (B) Exposure to d light at step 3 had a positive impact on
titan cells generation compared to incubation in the dark; (C) Raising the incubation temperature to 37˚C at step 3 decreased titan cells formation compared to 30˚C;
(D) Modification of the initial pH of the MM used at step 3 impacted titan cells formation with pH 5.5 being optimal while a more acidic (pH = 4), a neutral (pH = 7)
or an alkaline (pH = 8.5) pH inhibited titan cells formation; (E) The impact of hypoxia was tested by physical (closed cap) and by chemical (COCl2 in MM at 1 nM)
method and compared to normoxia (21% oxygen). Physically- and chemically-induced hypoxia enhances the production of titan cells compared to normoxia with a
higher proportion of titan cells in chemically- compared to physically-induced hypoxia. All experiments were performed in triplicate and pooled (mean cell
counted ± SD = 2305±1438). Median and IQR are shown in black for each condition ( p<0.0001 vs reference condition). The percentages above each condition
represents the % of titan cells observed.
https://doi.org/10.1371/journal.ppat.1006982.g004
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20 μm. Light exposure during step 3 also increased both median cell size and proportion of
titan cells (Fig 4B). In the light, median cell size was 9.4 μm [7.3–11.4] vs 8.4 μm [7.1–9.9] in
the dark, with a titan cell proportion of 41.6% (983/2362) vs 24.3% (1072/4399), respectively
(Fig 4B). Incubation temperature at 30˚C at step 3 increased cell size distribution compared to
37˚C (9.4 μm [7.3–11.4] vs 7.0 μm [6.2–8.2]) as well as the proportion of titan cells (41.6%
(983/2362) vs 8.1% (297/3652)) (Fig 4C). The pH of the minimal medium at step 3 also influ-
enced cell size (Fig 4D), with pH = 5.5 producing significantly larger cells and proportion of
titan cells (9.1 μm [6.9–11.2] and 38.6% titan cells), compared to either lower pH (pH = 4:
median 5.1 μm [4.4–5.8] (0%)) or higher pH (pH = 7: 8.2 μm [7.2–9.4] (16.4%), or pH = 8.5:
6.9μm [5.9–7.9] (0.7%)) (Fig 4D). Finally, hypoxia at step 3 also increased median cell size
compared to normoxia (7.5 μm [5.9–9.7]), with chemically induced hypoxia yielding higher
median cell sizes compared to physically induced hypoxia] (10.1 μm [7.8–12.5] vs 8.9 μm [7.3–
10.9, p<0.0001) (Fig 4E). The proportion of titan cells in normoxia (14.5% (732/5050) was
lower than in chemically induced hypoxia or physically induced hypoxia (63.0% (732/1161)
and 38.6% (1264/3004), respectively) (p<0.0001).
Generation of titan cells in vitro is influenced by host derived cues
We then tested hosts factors that could interact in vivowith yeast cells in the lung such as antic-
apsular antibodies, serum and phosphatidylcholine. Both serum and phosphatidylcholine have
already been implicated in titan cell formation [13,18,31]. Co-incubation at step 3 with monoclo-
nal antibodies that bind to different epitopes of the capsule inhibited titan cell generation, with a
decreased cell size of 7.2 μm [6.1–8.3] for E1 mAb, and 6.8 μm [5.9–7.7] for 18B7 mAb compared
to the untreated control (8.9 μm [7.1–10.6]) (Fig 5A), and a significantly smaller proportion of
titan cells (3.2% (44/1360) with 18B7, 5.3% (67/1273) with E1 compared to 33.1% (327/987) for
the untreated control). The addition of fetal calf serum (FCS) significantly decreased median cell
size (7.3 μm [6.4–8.1] vs (9.1 μm [7.1–11.1], Fig 5B) and the proportion of titan cells (2.5% (99/
3911) vs 38.2% (1234/3228), p<0.0001) compared to control, as did the addition of phosphati-
dylcholine (PC) (8.0 μm [7.0–9.0] vs 9.0 μm [7.1–11.2] for the median cell size, (Fig 5C) and the
proportion of titan cells (14.7% (344/2340) vs 38.2% (1077/2820), p<0.0001).
To understand if an alteration in yeast metabolism induced by ergosterol, protein or nucleic
acids inhibition affected titan cell formation, we tested the effect of co-incubation of flucona-
zole (inhibitor of ergosterol synthesis) and flucytosine (inhibitor of nucleic acids formation
and transcription) and cycloheximide (translation inhibitor) at step 3. Fluconazole (FLC)
exposure resulted in significantly smaller median cell sizes compared to the drug-free control
(7.1 μm [6.2–8.3]) at 1 mg/L, 6.8 μm [5.9–7.8] at 2 mg/L, and 6.5 μm [5.6–7.2] at 4 mg/L vs
9.4 μm [7.5–11.3] in the control, Fig 5D) and a significantly smaller proportion of titan cells
(5.9% (124/2073) at 1 mg/L, 2.9% (55/1919) at 2 mg/L and 1.0% (19/1877) at 4 mg/L vs 40.9%
(877/2146) in the control, p<0.0001, Fig 5D). Flucytosine exposure significantly decreased the
mean yeast cell size at all concentrations tested (6.5 μm [5.9–6.9] at 1 mg/L, 6.5 μm [6.1–6.9] at
2.5 mg/L, and 6.4 μm [5.9–6.8] at 5 mg/L compared to control (8.3 μm [6.8–10.3], Fig 5E) with
no titan cells observed upon flucytosine exposure. Cycloheximide exposure at 0.1 μg/mL also
significantly decreased the mean cell size from 9.0 μm [6.3–12.7] to 6.1 μm [5.5–6.9] (p<
0.0001) and the proportion of titan cells from 43.3% (797/1840) to 0.1% (20/1663) (Fig 5F). Of
note, the viability of the cells recovered at step 4 after 5 d of drug exposure was unchanged for
fluconazole but reduced for flucytosine and cycloheximide (p<0.0001 compared to unex-
posed, S6 Fig).
We also tested if iterative subcultures with or without the presence of active molecules
(CFW or fluconazole) affected titan cell formation, assuming that the cell wall and the global
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metabolism of the sub-cultured progeny would be impaired in the presence of high concentra-
tions of the cell wall toxic drug (CFW) or fluconazole, respectively. We analyzed the impact of
repeated sub-culture of the cells prior to step 1 on titan cell production (S7 Fig). Sub-culture
on Sabouraud agar eight times (8 Sub) spanning a one-month period significantly decreased
the median cell size (8.60 μm [7.02–10.07]) compared to the initial culture (0 Sub) (9.17 [6.99–
10.90]) (p<0.0001). Addition of CFW to induce cell wall stress during sub-culture (8Sub
+CFW) significantly decreased the median cell size (8.03 μm [6.82–9.46]) compared to the
8Sub control. Thus, iterative exposure to fluconazole during sub-culture significantly increased
the median yeast cell size to 10.15 μm [8.04–13.23] (8Sub+FLC) compared to the 8Sub control
(p<0.001, S7 Fig).
Generation of titan cells in vitro is influenced by quorum sensing molecules
Previous studies in a murine pulmonary infection model showed that inoculum concentration
can impact titan cell production [12,13]. To explore this phenomenon further, we examined
cell size changes in response to different initial concentrations of cells at step 3 (Fig 6A). Initial
cell concentrations significantly impacted the median cell size of the yeast population (p<
0.0001), with the highest median cell size observed at 106 cells/mL (9.2 [7.3–11.1]) compared
to 105 cells/mL (6.3 [5.1–8.3]), 104 cells/mL (6.2 [5.1–7.9]) and 107 cells/mL (5.9 [5.2–6.5]) (Fig
6A). Similarly, the proportion of titan cells was significantly higher at 106 cells/mL (37.6%
Fig 5. Titan cells generation in vitro is influenced in vitro by host derived cues and ergosterol, protein and RNA inhibitors. (A) Monoclonal anti-cryptococcal
capsular polysaccharide antibodies E1 and 18B7 (at 166 μg/mL in MM) significantly decreased cell size, as fetal calf serum (FCS, 5%) (B) and phosphatidylcholine at
5mM (C) did. (D) Fluconazole; (E) flucytosine at concentration below the MIC (4 mg/L) and (F) cycloheximide at 0.1μg/mL drastically impaired titan cells
formation with almost no titan cells produced upon drug exposure.
https://doi.org/10.1371/journal.ppat.1006982.g005
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(896/2382) compared to 10.3% (279/2716) at 104 cells/mL, 14.3% (346/2420) at 105 cells/mL
and 0% at 107 cells/mL (0/2177), p<0.0001. Previous study reported that pantothenic acid (PA
vitamin B5) is involved in quorum sensing and growth rate in C. neoformans [32]. The addi-
tion of PA had no effect on median cell size (8.35 μm [6.9–10.2] and 8.3 μm [6.4–10.8],
p = 0.8011, Fig 6B), but significantly increased the proportion of titan cells (37.9% (1435/3785)
Fig 6. Generation of titan cells in vitro is influenced by cell concentration and quorum sensing molecules. (A) The cell concentration at onset of step 2 significantly
modified titan cells generation with a maximal titan cells formation using an initial concentration of 106 cells/mL, and an abolition of titan cells formation at 107 cells/
mL; We then tested several factors at step 3 by adding (B) Pantothenic acid (PA) at 125 μM which had no impact on cell size distribution but significantly increased the
proportion of titan cells produced; (C) quorum sensing peptide 1 (Qsp1p, 10μM) which significantly decreased cell size distribution and the proportion of titan cells
produced; (D) The proportion of titan cells generated is influenced by the concentration of PA with a significant increase of titan cells at 0.125 μM and 12.5 μM (
p<0.001). (E) Growth curves were measured continuously during titan cells generation and showed a significant increase of the doubling time (slope) from 0.125 μM of
PA. Titan cells formation and growth rate is not correlated since titan cells formation is inhibited at 1250 μM of PA and the doubling time increased. (F) Qsp1 acts as a
repressor of titan cells formation as the addition of Qsp1 peptide inhibited titan cells formation (p<0.001). A control using scrambled peptide showed no effect on
titan cells formation. The qsp1Δ and pqp1Δ complemented by addition of Qsp1p showed an increase in titan cells formation. No effect of the Qsp1p was observed on
opt1Δ, the deletion mutant of the Qsp1 transporter Opt1. A specific titan cells inducing conditions was implemented for D, and E to allow induction of titan cells in a
100-well plate and continuous measurements of growth curves using the Bioscreen apparatus.
https://doi.org/10.1371/journal.ppat.1006982.g006
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vs 26.9% (983/3650)). In specifically implemented experimental settings, the proportion of
titan cells was influenced by the concentration of PA with a significant increase in titan cells at
0.125 μM (56.5 [50.6–61.1] and 12.5 μM (47.6 [35.6–50.3]) (Fig 6D). In parallel, analysis of the
growth curves of the yeast showed a significant increase in the doubling time (slope) at
0.125 μM of PA (Fig 6E), suggesting a lack of correlation between titan cell formation and
growth rate because titan cell formation was completely inhibited at 1250 μM of PA while the
doubling time increased.
Recent studies in C. neoformans also implicate the role of the small Qsp1 peptide in quorum
sensing [33]. Addition of Qsp1 peptide significantly decreased median cell size from 9.1 μm
[7.1–11.2] to 8.5 μm [6.9–10.1] (Fig 6C) and titan cell proportion from 38.4% (1075/2798) to
26.6% (915/3439), p<0.0001. Addition of Qsp1 peptide inhibited the formation of titan cells in
H99O (Fig 6C) and KN99α (Fig 6F). In the qsp1Δ, pqp1Δ and opt1Δ deletion mutants that can-
not produce or import a functional Qsp1 peptide [33], titan cell generation was increased com-
pared to KN99α, confirming the negative regulation of Qsp1 peptide in titan cell formation
(Fig 6F). When qsp1Δ, pqp1Δwere complemented with Qsp1 but not with scrambled Qsp1
peptides, titan cell formation was similar (increased titan cell formation) to that of the mutant
alone. The complementation of the opt1Δ deletion mutant with Qsp1 or scrambled Qsp1 did
not rescue the parental phenotype suggesting that the import of Qsp1 is crucial for its action
on the yeast cells (Fig 6F).
In vitro titan cell generation is dependent upon H99 genetic background
and requires functional LMP1, SGF29 and SREBP genes
Previous whole genome sequencing studies identified single-nucleotide polymorphisms
(SNPs) and insertions/deletions (indels) between H99-derived strains recovered from various
laboratories (Table 1) [34]. To determine whether any of these SNPs or indels affected titan
cell generation, we tested the H99S, H99W, H99 CMO18, H99L, KN99α strains. H99O pro-
duced significantly more titan cells than the other H99-derived strains, p<0.0001 (Fig 7A, S8A
and S9 Figs). These H99 derivative strains were also tested for titan cell formation in the lungs
of infected mice (S8A and S9 Figs). As with in vitro titan cell production, all the H99 derivative
strains showed lower levels of titan cell formation in vivowhen compared to H99O (p<
0.0001), with the exception of KN99α that had equivalent titan cell production to H99O (Fig
7A, S8A and S9 Figs).
Two genes, LMP1 and SGF29, are dramatically affected by SNPs/indels in the H99 deriva-
tives; LMP1 has a frameshift deletion (H99W and H99 CMO18) and SGF29 is deleted (KN99α
and H99L) [35]. To determine if these genes are involved in titan cell production, we analyzed
Table 1. Genes affected by SNPs or Indels in the different H99 strains.
Strains Genes affected Gene function Genetic event
H99O CNAG_07634 hypothetical Deletion
CNAG_04078 hypothetical Insertion
CNAG_06456 hypothetical Insertion
H99S CNAG_07595 hypothetical Deletion/frameshift
CNAG_12447 miscRNA Insertion
CNAG_12900 miscRNA Insertion
H99L CNAG_06392, SGF29 transcription factor (binds H3K4me2/3 and recruits histone deacetylation) Deletion
KN99α CNAG_06392, SGF29 transcription factor (binds H3K4me2/3 and recruits histone deacetylation) Deletion
H99W CNAG_06765, LMP1 Hypothetical (involved in mating virulence and melanization) Deletion/frameshift
H99 CMO18 CNAG_06765, LMP1 Hypothetical (involved in mating virulence and melanization) Deletion/frameshift
https://doi.org/10.1371/journal.ppat.1006982.t001
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lmp1Δ and sgf29Δdeletion mutants for in vitro and in vivo titan cell formation (Fig 7 and S8
and S9 Figs, respectively). In vitro, the sgf29Δmutant in the H99O background had half the
titan cell formation of the H99O wild-type strain [8.1% (49/600) to 4.2% (25/600), p<0.0001].
The sgf29Δmutant in the hypervirulent H99S also manifested no titan cells generation, as did
an lmp1Δmutant in this background. Complementation of LMP1 and SGF29 in this H99S
mutant restored titan cells generation to that found in the parental strain; 1.2% (13/935) and
1.4% (7/600), respectively vs H99S 1.6% (25/1540) (Fig 7B). Importantly, the same trend was
observed for in vivo titan cell formation. In vivo, the lmp1ΔH99S mutant produced only 3.5%
(21/600) titan cells compared to 14% for H99S (84/600), p<0.0001, and this decrease in titan
cell production was restored in the lmp1Δ:LMP1H99S strains (9.5% (57/600)) (S8B Fig). The
sgf29Δmutant in the H99O background reduced titan cell formation in vivo from 18.8% (113/
Fig 7. Titan cells generation is dependent on various genes and requires signaling through the Gpr/PKA/Rim101 pathway in vitro. (A) The different H99 strains
harbored variable abilities to produce titan cells compared to H99O (grey bar) with high titan cells producer (H99O, S, L) and low titan cells producer (KN99α,
H99W, H99 CMO18) in vitro. (B) Sgf29Δand lmp1Δ deletion mutants show a decrease in titan cells generation in various H99 backgrounds in vitro compared to
H99O. Complementation in strains lmp1Δ:LMP1 and sgf29Δ:SGF29 in H99S background restored the phenotype of H99S. Rim101 (C) and GPR4 and GPR5 and
CAC1 (D) are required for titan cells generation in vitro in H99 and KN99α. The ratio to the value obtained for H99O used as a calibrator in each experiment was
calculated for each strain. Bar represent mean ± SD (mean cell counted = 600). Khi2 test was performed to compare the experimental conditions to H99O, they were
performed in triplicates and pooled (p<0.0001, p<0.0001, when the comparison was done with the parental strain H99S).
https://doi.org/10.1371/journal.ppat.1006982.g007
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600) to 9.3% (37/400) (p<0.0001). In H99S, complementation of Sgf29 (sgf29Δ:SGF29) in
H99S restored titan cell generation to wild-type H99S levels from 5% (30/600) to 19.8% (237/
1200) (Fig 7B, S8B Fig) (p<0.0001).
SREBP is a gene involved in response to hypoxia, so we tested titan cell formation in the
sre1Δmutant. The proportion of titan cells was significantly decreased in the sre1Δmutant at
5.1% (53/920) compared to KN99α [14% (337/2358)] (p<0.0001) (S10 Fig).
In vitro titan cell generation requires signaling through the Gpr/PKA/
Rim101 pathway
The signal transduction pathway Gpr/PKA/Rim101 regulates titan cell formation in vivo [18].
Briefly, the G-protein coupled receptor 5 and Ste3a pheromone receptor signal through Gpa1
to trigger the cAMP/PKA signaling cascade, ultimately activating the Rim101 transcription
factor. This pathway regulates virulence factors such as capsule or melanin [36,37].
To determine if this same pathway was critical for titan cell generation in vitro, we exam-
ined cell enlargement in the gpr4Δ, gpr5Δ, gpr4Δ/gpr5Δ, rim101Δ, and cac1Δmutants and their
complemented strains in both the H99 and KN99α genetic backgrounds (Fig 7C and 7D, S9
Fig). In the H99O genetic background, Rim101 function was similar to that observed in vivo,
with little titan cell formation in the rim101Δmutant (1.9% (51/2600)) and full restoration of
titan cell production in the complemented strain (9.2% (239/2600) (p<0.0001) (Fig 7C). In
KN99α, the rim101Δ, gpr4Δ/gpr5Δ, and cac1Δmutants had no titan cell formation, but surpris-
ingly both of the single gpr4Δ and gpr5Δmutants also lacked titan cell formation (Fig 7D). This
is in contrast to in vivowhere titan cell production was rescued by GPR5 alone [18]. Taken
together, these data suggest that signaling through both Gpr4 and Gpr5 via the cAMP/PKA
pathway to Rim101 is required for titan cell production in vitro.
In vitro titan cell formation is regulated by PKR1 in clinical isolates
To determine whether the Gpr/PKA/Rim101 pathway can impact titan cell formation in clini-
cal isolates, we also screened a total of 56 clinical isolates for their ability to produce titan cells.
Two isolates (AD2-06a and AD2-02a) produced a more titan cells relative to H99O (ratio of
clinical strain/H99O of 2.6±0.3 and 1.4±0.3, respectively). Three additional isolates (AD4-37a,
AD1-95a, AD4-43a) produced fewer titan cells than H99O (ratio = 0.4±0.3, 0.2±0.1, 0.1±0.0,
respectively). Titan cell production in the other clinical isolates was close to zero (ratio between
0.1 and 0.01% for five, less than 0.01% for six, and no titan cells at all for the remaining 39 iso-
lates) (Fig 8A).
The complete genome sequence was obtained for 41 of the 68 screened clinical isolates and
a phylogenetic tree of these strains and the H99O reference strain shows high genetic diversity
including VNI, VNII, VNBII isolates (Fig 8B, Table 2). Compared to H99O, the high titan cells
generating strain AD2-06a harbored 31,229 SNPs and was closely related to AD3-55a (31,171
SNPs) and AD3-41a (28,599 SNPs), which were both unable to produce titan cells. A total of
19 genes, including CNAG_00570 (PKR1), were disrupted in AD2-06a and not in AD3-55a
and AD3-41a (S1 Table). Of note, no common genetic mutation, insertion or deletion was
observed in the 3 strains that produced a significant (>1%) proportion of titan cells (H99O,
AD2-06a, AD1-95a) as compared to all the other examined isolates. Duplication of chromo-
somal regions were observed in the French sequenced clinical isolates (S2 Table) with AD2-
06a harboring a large duplication of chromosome 9 (Chr9, region 465–665kb). To assess
whether the Chr9 duplicated region could be responsible for titan cell formation, we explored
a larger collection of C. neoformans strains with complete genome sequences [38] and discov-
ered five additional clinical isolates (Ug2459, CCTP20, FFV14, WM-148, WM-626) harboring
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Fig 8. Non-synonymous mutation of PKR1 enhances titan cells generation based on clinical isolates analysis. (A) The screening of 56 C.
neoformans serotype A MATα french clinical isolates identified isolates AD2-06a (ratio = 2.6±0.2) and AD2-02a (ratio = 1.4±0.2) as titan cells
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partial duplications on chr9 duplication (S11 Fig). We analyzed titan cell formation in these 5
isolates, but only the Ug2459 strain generated titan cells in vitro and only at a low proportion
(S11 Fig), suggesting that genes located within in the AD2-06a Chr9 duplication are not
involved by themselves in titan cell formation.
AD2-06a was isolated from the initial cerebrospinal fluid (CSF) sample of an HIV-infected
patient at baseline (diagnosis of cryptococcosis). Another isolate, AD2-07, was recovered from
the CSF of the same patient after 13 d of amphotericin B treatment. Thus, AD2-06a and AD2-
07 are closely related with only 137 different SNPs and 40 indels. AD3-55a is in the same clade
and also very similar with 370 different SNPs and 64 indels, although recovered from another
producers compared to H99O (grey bar); (B) Phylogenic tree of the isolates (n = 41) for which the whole sequence was available [38,39] was
estimated using RAxML under the GTRCAT model. This shows that AD2-06a, AD2-07 and AD3-55a are phylogenetically close together. (C)
Venn diagram representing the number of common or specific SNPs and Indel between AD2-06a, AD2-07 and AD3-55a. One of the four AD2-
06a specific SNPs is a non-synonymous mutation in the PKR1 gene (mutation Gly125fs); (D) Alignment of Pkr1 protein sequences from selected
clinical isolates including H99O and AD2-07 that both harbor a wild type sequence. The Pkr1 domain architecture is formed by a dimerization
domain in green (amino acids 2 to 40) and two cAMP binding sites based on INTERPRO model in red (amino acids 219 to 351 and 353 to 473).
(E) Strains with PKR1 loss-of-function mutation showed a variable ability to produce titan cells, as compared to H99O (grey bar). The clinical
isolate AD2-07, which produces significantly less titan cells was recovered from the CSF of an HIV-positive patient on d 13 of amphotericin B
treatment while AD2-06a, which produced the highest proportion of titan cells, was recovered from the initial CSF sample of the same patient. (F)
Complementation of PKR1 gene (AD2-06a:PKR1) in the naturally deficient strain AD2-06a reduced titan cells generation compared to AD2-06a.
The ratio to H99O, used as a calibrator in each experiment, was calculated for each strain (panel A, E, F) and results expressed as mean ±SD.
Experiments A, F and G were done in triplicate, B twice (screening). To compare the experimental conditions to H99O, Khi2 analysis was
performed (p<0.0001, p<0.05). Mean cell counted ± SD = 1165±528.
https://doi.org/10.1371/journal.ppat.1006982.g008
Table 2. Alignment and SNP statistics of sequenced isolates using H99 as a reference.
Strain MLST genotype % of Assembly Covered by aligned reads Alignment depth (X) SNPs
AD3-55a unique 100 133 28,070
AD2-06a unique 100 129 28,202
AD2-07 unique 99 45 27,797
AD3-41a unique 100 134 25,378
AD4-92a A3/M3 100 132 11,906
AD4-47a A4/M1 100 132 10,018
AD3-58 A4/M1 100 123 9,996
AD3-83a A1/M1 100 166 172
AD2-99a A1/M1 100 119 180
AD6-55a related to A1/M1 100 108 12,440
AD6-54a related to A1/M1 100 131 12,440
AD5-45a related to A1/M1 100 142 12,417
AD1-95a related to A1/M1 100 107 12,521
AD1-90a related to A1/M1 100 122 12,511
AD5-67a VNII 100 139 277,381
AD3-9a VNII 100 111 277,417
AD3-11a VNII 100 125 268,842
AD4-76a Th 100 112 43,281
AD3-95a Th 100 141 43,235
AD5-53a A5/M5 100 130 42,291
AD2-82a A5/M5 100 133 42,271
AD1-86a A5/M5 100 105 43,778
AD5-39a A4/M4 100 108 43,696
AD4-63a A4/M4 100 129 43,736
AD2-04a A4/M4 100 137 43,733
AD1-68a A4/M4 100 132 43,778
https://doi.org/10.1371/journal.ppat.1006982.t002
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patient and in another place (Fig 8B and 8C). By contrast, these three isolates differ from
H99O by 29,000 SNP and 3,386 indels. AD2-07 and AD3-55a were both unable to produce
titan cells (Fig 8A, 8B and 8E), allowing a more fine-scale analysis of SNPs linked to titan cell
formation in these closely related strains (Fig 8C). Specifically, AD2-07 produced 1.0% (31/
3047) titan cells compared to 39.1%, (639/1633) in AD2-06a and 15.2% (304/2001) in H99O
(p<0.0001). The median cell size of AD2-07 was significantly decreased compared to AD2-06a
and H99O (5.9 μm [5.2–6.6] for AD2-07, 8.5 μm [7.0–13.0] for AD2-06a, and 7.7 μm [6.5–9.2]
for H99O, p<0.0001, S12 Fig).
Comparison of the AD2-06a, AD2-07, and AD3-55a genomes identified four genes with
loss-of-function mutations in AD2-06a but not in AD2-07 or AD3-55a: CNAG_00570 (PKR1)
(Fig 8D), CNAG_07475 (hypothetical protein), CNAG_01240 (hypothetical protein) and CNAG_
05335 (hypothetical protein). More precisely, AD2-06a had a frameshift mutation at glycine 125 in
the CNAG_00570 (PKR1) leading to a truncated protein of 138 amino acids (Fig 8D). Pkr1 is the
cAMP-dependent protein kinase regulatory subunit that interacts with Pka to regulate the phos-
phorylation activity of Pka. To further explore PKR1 in clinical isolates, we analyzed additional,
previously sequenced, clinical isolates (S3 Table) that harbored mutations leading to Pkr1 trunca-
tion (Bt156, Bt58, 8–1, Bt77, Bt117, Ug2462) for titan cell formation [39]. Specifically, a frameshift
mutation at amino acid 14 introducing a premature stop codon at position 96 for Bt156, as well as
stop codons introduced at positions 130 for AD2-06a, 258 for Bt58, 302 for 8–1, 439 for Bt77, 441
for Bt117, and 445 for Ug2462 were observed (Fig 8D, Table 3). We hypothesized that the strains
with highly impacted/truncated Pkr1 protein would produce more titan cells, similar to the AD2-
06a isolate. AD2-06a and Bt156, the strains with the largest truncation, had high levels of titan cell
formation with a ratio of 2.8±1.0 for AD2-06a and 1.3±0.6 for Bt156 compared to H99O (Fig 8E),
and titan cell proportions and median cell sizes of 39.1% (639/1633) (median 8.5μm [7.0–13.0])
and 17.9% (469/2614) (median 7.7μm [6.4–9.4]), respectively (S12 Fig). For the other strains, the
ratio, proportion of titan cells, and median size were decreased compared to H99O: 0.2±0.0, 3.6%
(89/2464) and 6.9 μm [6.0–7.8] for 8–1 strain; 0.2±0.1, 2.9% (110/3834) and 6.5 μm [5.8–7.1] for
Bt77; 0.1±0.0 0.9% (27/3081) and 6.4 μm [5.7–7.2] for Bt117; and 0.1±0.1, 1.5% (54/3628) 5.4μm
[4.7–6.1] for Ug2462, p<0.0001) (Fig 8E, S12 Fig).
To directly test whether the truncated Pkr1 protein impacted titan cell production in strain
AD2-06a, the functional KN99α allele of the PKR1 gene was introduced into the strain (AD2-
06a:PKR1) and titan cell formation analyzed. Titan cell production was significantly decreased
Table 3. Mutations of PKR1, CAC1, USV101 in specific clinical isolates.
Gene Strains Mutations
PKR1 Ug2462 n.1333C>T|p.Arg445|1333/1449
Bt117 n.1274_1280dupCTCTCCT|p.Asn428fs|1280/1449
Bt77 n.1293dupA|p.Arg432fs|1293/1449
8–1 n.878_911delCCGAGGGGAGCTCGTTTGGGGAGTTAGCGCTGAT|p.Ser293fs|911/1449
Bt58 n.742G>T|p.Glu248|742/1449
AD2-06a n.375_376delAG|p.Gly125fs|376/1449
Bt156 n.41dupA|p.Asp14fs|41/1449
CAC1 Bt133 n.41delA|p.His14fs |41/6930
8–1 n.2_3insA| |p.Met1fs|2/6930 ; n.80G>A|p.Trp27|80/6930 ; n.81G>A|p.Trp27|81/6930
AD3-11a n.2_3insA| |p.Met1fs|2/6930
AD3-9a n.2_3insA| |p.Met1fs|2/6930
AD5-67a n.2_3insA| |p.Met1fs|2/6930
Ug2462 n.2_3insA| |p.Met1fs|2/6930
USV101 Bt88 n.842dupC|p.His282fs
https://doi.org/10.1371/journal.ppat.1006982.t003
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by complementation (p<0.0001) with 44.9% (574/1279) for AD2-06a:PKR1 as compared to
64.6% (700/1083) for AD2-06a and 23.2% (555/2363) for H99O (Fig 8F).
To further explore the function of PKR1 in titan cell formation, we also tested the ability of
pkr1Δ in a KN99α background to generate titan cells compared to KN99α, and found that
pkr1Δ produced more titan cells with a ratio of 4.9±1.6 compared to the parental strain KN99α
(Fig 9). The pkr1Δmedian cell size (8.1 μm [6.7–9.5]) exceeded that of KN99α (6.4 μm [5.5–
7.2]) p<0.0001) with a significant increase in the proportion of titan cells at 28.5% (695/2436)
for pkr1Δ vs 4.6% (121/2614) for KN99α (p<0.0001, Fig 9A). We also analyzed titan cell pro-
duction in two additional independent pkr1Δ and complemented pkr1Δ:PKR1 strain in the
H99 background. The pkr1Δ-1 and complemented pkr1Δ:PKR1-1 gave ratios of 2.9±1.5 and
1.8±0.7, respectively, while the pkr1Δ-2 and complemented pkr1Δ:PKR1-2 ratio were 1.9±0.8
and 1.4±0.4, respectively, compared to the H99 parental strains (1.0±0.5) (Fig 9B). In both
strains, complementation significantly reduced the proportion of titan cells generated (p<
0.0001) from 29.8% (685/2493) for pkr1Δ-1 to 18.8% (593/3217) for pkr1Δ:PKR1-1; and from
19.9% (422/2364) for pkr1Δ-2 to 13.9% (359/2588) for pkr1Δ:PKR1-2with H99 at 10.3% (357/
3674). We also tested the role of PKA1 and PKR1 using the galactose-inducible and glucose-
repressible versions of PKA1 and PKR1mutants [6]. In these mutants, when incubated in
galactose minimal medium (Fig 9C), the genes are turned on whereas when incubated in glu-
cose minimal medium the genes are turned off (Fig 9D). In galactose minimal medium,
PGAL7::PKA1 and PGAL7::PKR1 had titan cell production ratios of 5.6±1.1 and 0.6±0.5 com-
pared to H99, respectively. The proportion of titan cells was significantly increased upon
PKA1 induction [46.9% (794/1724)] and reduced by PKR1 induction [4.7% (222/5031)] com-
pared with H99 in galactose minimal medium at 14.8% (402/3108) (p<0.0001, Fig 9C). In glu-
cose minimal medium, PGAL7::PKA1 and PGAL7::PKR1 had titan cell production ratios of 0.0
±0.0 and 2.4±1.0, respectively. The proportion of titan cells was significantly decreased upon
PKA1 repression [0.2% (6/4156)] and increased by PKR1 repression [25.4%(527/2425)] com-
pared with H99 at 10.3% (357/3674) (p<0.0001, Fig 9D).
At least 2 other genes (TSP2,USV101) have been linked to titan cells formation in vivo
although their role is less clear, so we directly explored their phenotypes in our in vitro proto-
col. To examine the role of tetraspanin 2 (Tsp2) in titan cell formation in vitro, we analyzed
three independent tetraspanin 2 deletion mutants (tsp2Δ-1, tsp2Δ-2 and tsp2Δ-3) and two com-
plemented mutants (tsp2Δ-1:TSP2-1 and tsp2Δ-1:TSP2-2) for their titan cell formation com-
pared to the wild-type KN99α. Titan cell production was significantly increased in the deletion
mutants (23.9% (518/2161) for tsp2Δ-1, 55.7% (990/1778) for tsp2Δ-2, 44.3% (714/1610) tsp2Δ-
3, 4.6% (119/2576)) compared to the wild-type and complemented strains (tsp2Δ-1:TSP2-1,
5.8% (228/3877) for tsp2Δ-1:TSP2-2 and 4.9% (173/3472) for KN99α) (p<0.0001) (Fig 9E).
Similarly, usv101Δmedian cell size (10.6 μm [8.7–12.7]) was higher than the parental strain
KN99α (7.6μm [6.6–8.8]) and the proportion of titan cells was 62.7% (1260/2008) for usv101Δ
vs 10.5% (238/2262) for KN99α (p<0.0001) (S9 Fig).
We finally selected additional sequenced clinical isolates that harbored mutations leading
to Usv101 or Cac1 truncation. Bt88 showed a truncation of Usv101 and an increased titan cells
formation ratio of 0.6±0.4 whereas the other isolates belonging to the VNBII lineage harboring
a CAC1mutation (Bt133 and Bt31, Bt40, Bt89 and Bt105) did not show increased titan cells
formation (ratio 0.0±0.0) (S13 Fig).
Discussion
We identified and validated a new protocol allowing robust generation of titan cells in vitro.
This protocol was discovered serendipitously while testing conditions that could induce
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dormancy in C. neoformans [4]. We observed yeast cell enlargement under defined growth
conditions, then optimized those conditions for titan cell production. It is important to note
that the utility of other published protocols to generate titan cells in vitro are hindered by issues
with inter-laboratory reproducibility [12,31]. To establish the inter-laboratory transferability
of our protocol, we independently tested it in two other laboratories (K. Nielsen and A. Casa-
devall) and observed that the protocol produced similar results in all laboratories, although
slight variations of the materials and equipment used produced subtle variability in the per-
centage of titan cells generated in the 3 labs. Interestingly, titan cell production in vitro was
also optimized by Ballou et al. 2017 and Zaragoza et al. 2017, using a different set of growth
conditions [40,41]. Exploration of the similarities and differences between these protocols will
likely identify the critical environmental conditions that trigger titan cell production in vivo.
Titan cells obtained in vitro exhibited many of the characteristics of in vivo titan cells recov-
ered from the lungs of infected mice [17]. Similar to previous work on in vivo titan cells, we
defined the in vitro titan cells as having a cell body size > 10 μm and typical cells with a cell
body size 10 μm [12,13,18,21]. Titan cells generated with our in vitro protocol were also
polyploids, as previously shown in vivo [12,13]. Melanization was increased in in vitro titan
compared to typical cells. Capsule size was slightly increased in the in vitro titan cells compared
to typical cells, but this difference was lower than previously shown in vivo [12,13]. We also
demonstrated that, regardless of the capsule size differences between in vitro and in vivo titan
cells, the structure of the in vitro titan cell capsule was different to that in typical cells, a phe-
nomenon also observed in vivo [13,22]. The cell wall was thicker in in vitro titan cells com-
pared to typical cells, as previously analyzed in vivo [22,31,42]. The increased chitin in the titan
cell wall results in a detrimental immune response that exacerbates disease[42]. These findings
suggest a fundamental difference in titan and typical surface structure that may contribute to
reduced titan cell phagocytosis [12,13,21]. These cell surface differences also underscore the
complex regulation of these major virulence factors and shows intricate adaptation of C. neo-
formans to both in vitro and in vivo conditions.
Titan cell generation in vitro allowed a detailed kinetic analysis that revealed titan cells are
formed between 4 and 8 h. Using calcofluor white staining to follow cell fate and cell division
[4,30], we showed that titan cells were exclusively derived from cells present in the initial inoc-
ulum that evolved progressively toward the titan cell phenotype. In contrast, typical cells were
a mixture of cells from the initial inoculum and new cell replication. Titan cell division pro-
duced typical sized haploid cells, as shown previously for in vivo titan cells [12,13] and con-
firmed in our study. We published in vivo data that validate this observation [4]: using yeasts
recovered from the lung of mice at one week after inoculation of C. neoformans stained with
calcofluor and multispectral imaging flow cytometry, we showed that the CalcofluorHigh popu-
lation was associated with yeast cells harboring high cell size parameters compatible with titan
cells [4]. In vitro, titan cell generation coincided with the appearance of a large vacuole in the
yeast cells at 4 and 8 h of incubation. Recent evidence places vacuoles at the center of networks
Fig 9. In vitro titan cells generation is dependent on the negative regulator PKR1 and TSP2. (A) PKR1 is a repressor
of titan cells formation in KN99α background and (B) in H99 background. (C) in galactose mimimal medium
(galactose MM), GAL7 promoter upstream of the PKA1 and PKR1 genes induced an increased titan cells formation for
PKA1 and a decreased titan cells formation for PKR1 (D) In minimal medium with glucose (glucose MM)), GAL7
promoter induced a repression of titan cells formation for PKA1 and an induction of titan cells formation for PKR1.
(E) Tetraspanin 2 (TSP2) is a repressor of titan cells formation. Complementation of the deletion mutants restored the
phenotype of KN99α. The ratio to H99 or KN99α, used as a calibrator in each experiment, was calculated for each
strain (panel A to E) and results expressed as mean ± SD. Experiments A to G were done in triplicate. To compare the
experimental conditions to H99O, Khi2 analysis was performed (p<0.0001 vs control H99 or KN99α or appropriate
mutants).
https://doi.org/10.1371/journal.ppat.1006982.g009
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enabling nutrient resources to be degraded, sorted and redistributed [43]. As the vacuole vol-
ume occupies much of the total volume of the titan cell body, one can imagine that cell-cycle
regulation could be impacted, ultimately leading to polyploidy [20].
The fact that our in vitro protocol consistently produced titan cells also allowed us to test
factors that influenced their appearance. In terms of environmental factors, we showed that
titan cell production was influenced by pre-culture medium, initial pH, light exposure, tem-
perature, type of medium and hypoxia. A metabolic switch between YPD (rich medium) pre-
culture and minimal medium (poor medium) incubation was a key factor to induce titan cell
generation. This switch is a stress that induces many metabolic modifications and has been
studied extensively in Saccharomyces cerevisiae [44]. Hypoxia is another stress factor encoun-
tered by human pathogenic fungi during infection [45], and a strong signal for titan cell pro-
duction in vitro. Oxygen levels in healthy human tissues are 20–70 mmHg (2.5–9% O2), but
can be less than 10 mmHg (*1% O2) in hypoxic or inflamed tissues or inside granulomas
[46]. We know from previous work on pulmonary aspergillosis that hypoxia has been observed
in infected lungs of mice [47]. Titan cells have been reported in human pulmonary cryptococ-
cosis and well-studied in murine pulmonary infection following inhalation [12–13, 15–21],
although they are also observed in mouse lungs after intravenous inoculation of animals [4].
These observations lead us to hypothesize that low oxygen levels in the lungs could be a signal
for titan cell formation. A major transcriptional regulator of the fungal hypoxia response is the
sterol regulatory element-binding protein (Srebp) [48]. Deletion mutants of the SREBP gene
(sre1Δ) in C. neoformans display defects in adaptation to hypoxia, ergosterol synthesis, suscep-
tibility to triazole antifungal drugs and cause a reduction of virulence [48]. Importantly, the
sre1Δmutant also showed defects in titan cell production in vitro, highlighting the role of hyp-
oxia in titan cell production.
Interestingly, quorum sensing is also involved in titan cell production. Indeed, the initial
concentration of yeasts in minimal medium dramatically impacted titan cell generation, with
106 cells/mL being the optimal cell concentration to generate titan cells in vitro. No titan cell
formation was observed with a starting concentration of 107 cells/mL, likely due to rapid con-
sumption of the nutrients preventing metabolic modifications needed to generate titan cells.
Alternatively, addition of the quorum Qsp1 peptide [33,49] to wild type cultures (already pro-
ducing Qsp1) decreased titan cell production, suggesting that Qsp1 negatively regulates titan
cell production. Cleavage and internalization of Qsp1 were critical because the qsp1Δ, pqp1Δ,
opt1Δmutants all showed increased titan cell production. Pantothenic acid (vitamin B5) has
also been implicated in quorum sensing in C. neoformans [32]. Addition of pantothenic acid
dramatically increased titan cell formation at concentrations between 0.125 and 12.5 μM.
These results demonstrate that intercellular communication is important for titan cell forma-
tion and that this sensing process involves cell-cell communication instead of simple nutrient
sensing.
Induction of titan cells due to the presence of host factors such as temperature, addition of
lipids, presence of serum, and antibodies was also tested. The presence of E1 [50] and 18B7
[51] anti-capsular IgG antibodies decreased titan cell production. This decrease could be
related to changes in yeast metabolism induced directly by anti-capsular antibodies, as shown
previously [52], and provides a new mechanism by which antibodies could alter the course of
infection. One could imagine that specific anti-capsular antibodies may not reach cryptococcal
cells in the alveolar space at sufficient concentration to impair enlargement. The presence of
surfactant protein-D, considered as an opsonin in the lung, could impair antibody fixation
[53], thus inhibiting the inhibitory effect of IgG antibodies and allowing titan cell formation in
the lung. Interestingly, addition of serum (5% FCS) or L-α-phosphatidylcholine decreased
titan cell production, which is different from other protocols for titan cells generation [40,41].
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This difference may be because our protocol induces titan cells through parallel or indepen-
dent pathways to those triggered by serum or lipids. Overall, these results imply the existence
of numerous triggers for titan cell formation mediated through independent signaling path-
ways. How these pathways ultimately interact, both positively and negatively, to regulate titan
cell production still needs to be explored.
Titan cell production was inhibited by addition of fluconazole, flucytosine and cyclohexi-
mide—even at concentrations that or below the MIC of the drug. Fluconazole is known to
inhibit the 14-alpha-demethylase (Erg11) involved in ergosterol synthesis, leading to plasma
membrane instability and accumulation of toxic precursors [54]. Flucytosine is a base analogue
leading to inhibition of DNA replication and protein synthesis [55]. Cycloheximide is known
to impact protein synthesis through inhibition of translation [27]. Thus, titan cell production
likely involves an active process requiring protein and nucleic acid production, as well as
plasma membrane integrity (normal ergosterol quantity). Conversely, serial passage in the
presence of fluconazole increased titan cell production, suggesting compensatory changes in
response to fluconazole also impacted titan cell production. These data have profound implica-
tions for in vivo titan cell production, as prolonged drug therapy could prevent or enhance
titan cell formation. In previous studies, exposure of titan cells to fluconazole selected for aneu-
ploidy and drug resistance in the daughter cells [20]. In contrast, our studies show exposure to
cell-wall stress, induced by serial passage on CFW agar, decreased titan cell production. In
these sub-culture experiments, we did not investigate subsequent genomic or metabolic
changes that arise under these stress conditions. Serial sub-culture could have induced genetic
rearrangements (aneuploidy, SNPs, indels) or epigenetic variation that altered titan cell
production.
Our protocol is easy to implement for study of the molecular and genetic mechanisms
underlying titan cell generation. Our in vitro assay allowed us to identify host, environmental
and yeast factors that impact titan cell production. By taking advantage of strains harboring
genetic differences and clinically relevant genetic truncations, we were able to assess genetic
factors modulating titan cell production. However, these studies also highlight that variability
in titan cell formation cannot be completely explained by the acquisition of genetic events,
with H99-derivative strains showing diversity in titan cell production that does not fully corre-
late with genetic modifications. The observation that titan cell formation in KN99α differs in
vitro (lower than H99O) and in vivo (equivalent to H99O) highlights this issue and suggests
further strain adaptation that are yet to be characterized.
We uncovered new genes involved as positive or negative regulators of titan cell produc-
tion. Sgf29, is a component of the SAGA complex that binds H3K4me2/3 and recruits histone
deacetylases in S. cerevisae [56]. The LMP1 gene is known to be involved in virulence in a
mouse model and in mating [34]. We showed here that both genes are positive regulators of
titan cell formation, although their mechanism of action remains unclear. We also showed in
vitro the critical role of the Gpr/PKA/Rim101 pathway in titan cell formation, previously char-
acterized in vivo [18]. Gpr5 signals through Gpa1 to trigger the PKA pathway that activates the
transcription factor Rim101 [18,36]. In addition, we identified three genes that are negative
regulators of titan cell formation, including PKR1 (known to act as a regulatory subunit in the
PKA pathway [23], TSP2 that encodes a glucose repressor of laccase in C. neoformans [57], and
USV101 that is a pleiotropic transcription factor in C. neoformans known to regulate capsule
formation and pathogenesis [58].
In Saccharomyces cerevisiae, the Pka1/Pkr1 complex is a heterotetramer with 2 catalytic sub-
units and 2 regulatory units. This complex is dissociated in the presence of cAMP [59]. More-
over, the architecture of the functional domains of Pkr1 include one interaction domain/
dimerization at amino acids 2 to 40 and two cAMP binding domains at amino acids 219 to 351
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and 353 to 473, based on INTERPRO data (Fig 8D). Consequently, the cAMP binding domain
on Pkr1 is critical for the dissociation of the PKA1/PKR1 complex. Analysis of differences in
titan cell production, combined with complete genome sequencing, allowed us to identify nat-
urally occurring mutations in the PKR1 gene that impact titan cell production. Both PKR1
mutations have a stop codon (Gly125fs for AD2-06 and Asp14fs for Bt156) that reduces the
protein length. Interestingly, AD2-06a was the incident clinical isolate and a recurrent isolate
recovered after 13 days of amphotericin treatment (AD2-07) did not harbor this PKR1 muta-
tion. In addition, a PKR1mutation leading to intron retention was found in a relapse isolate
[60] and shown to be associated with less virulence than the incident isolate. Whether the viru-
lence differences observed with the relapse isolates are linked to titan cell formation needs to
be further investigated.
We identified TSP2 as a negative regulator of titan cell formation based on deletion mutants
and complemented strains. TSP2 is known to interact with the cAMP/PKA pathway—tsp2Δ
mutant strains phenotype are reversed by the addition of cAMP [57]. These data suggest that
TSP2 inhibits the cAMP pathway and reinforces the major role of cAMP in titan cell forma-
tion. No natural TSP2mutants were observed in our collection of clinical isolates.
Interestingly, all isolates from the VNBII have a mutation in the CAC1 gene leading to the
functional defect of the Cac1 protein. Out of the six VNBII isolates (Table 3), only Bt88 that
harbored an additional functional abolition of Usv101 was able to produce as much titan cells
as H99O did. Therefore, in Bt88, titan cell formation resulted in the equilibrium between the
abolition of CAC1 (positive regulator) and USV101 (negative regulator).
Altogether, these results show proof of concept that our in vitro protocol can be used to
identify and characterize genes required for titan cell production. Our preliminary analysis
only identified a handful of genes involved in titan cell production, but it is likely that many
more are involved in generation of this complex cell morphology. Our data provide new
insights into the genesis of titan cells and the environmental, host and genetic factors that
influence their production. Finally, our data show that this in vitro protocol can be used to
reproducibly generate titan cells that have similar characteristics to titan cells generated in
vivo. The conditions identified for titan cell formation provide a robust system that could be
invaluable to dissect the molecular mechanisms that underlie titan cell formation and allow
the identification of naturally occurring mutations that regulate titan cell formation. These
studies will enhance our understanding of the impact and mechanisms of yeast morphological
changes on pathobiology.
Material and methods
Ethics statement
Mice (purchased from Jackson Laboratories, Bar Harbor, ME) were handled in accordance
with guidelines defined by the University of Minnesota Animal Care and Use Committee
(IACUC), under approved protocol numbers 1010A91133 and 130830852, and in accordance
with the protocols approved by JHSPH IACUC protocol M015H134. All animal experiments
were performed in concordance with the Animal Welfare Act, United States federal law, and
NIH guidelines.
Strains and culture medium
The strains and clinical isolates of C. neoformans used in the study are listed in S4 Table. The
study was started with H99 strain called H99O that was kindly provided by J. Heitman (Duke
University, Durham, NC) in the late 90’s. The reference strain KN99α and strains from the
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Madhani collection were provided from Kirsten Nielsen’s lab and the Fungal Genetic Stock
Center [61], respectively.
C. neoformans strains were grown in liquid Yeast Peptone Dextrose (YPD, 1% yeast extract
(BD Difco, Le Pont de Claix, France) 2% peptone (BD Difco), 2% D-glucose (Sigma, Saint
Louis, Minnesota, USA)) and in minimal medium (MM, 15mM D-glucose (Sigma), 10 mM
MgSO4 (Sigma), 29.4mM KH2PO4 (Sigma), 13mM Glycine (Sigma), 3.0 μM Thiamine (Sigma),
[32]). Minimum inhibitory concentration (MIC) of H99O for fluconazole (FLC) and flucyto-
sine (5FC) (both purchased from lsachim, Shimadzu Group Company, Illkirch-Graffenstaden,
France) were determined by the EUCAST method and were 8 and 4 mg/L, respectively.
In vitro protocol for titan cells generation
C. neoformans strain from stock cultures stored in 20% glycerol at -80˚C was cultured on
Sabouraud agar plate at room temperature (step 1). After 2 to 5 d of culture, approximately 107
cells were suspended in 10 mL YPD in a T25cm3 flask and cultured 22 h at 30˚C, 150 rpm with
lateral shaking until stationary phase (final concentration = 2x108cells/mL) (step 2). Then, one
mL of the suspension was washed twice with MM. The cell concentration was adjusted to 106
cells/mL in MM and the suspension was incubated in a 1.5 mL tube (Eppendorf) with the cap
closed, at 30˚C, 800 rpm for 5 d using an Eppendorf Thermomixer1 (Hamburg, Germany)
(step 3). Cell size was determined as described below. Cells with body size >10 μm were con-
sidered as titan cells as described [12]. Results are expressed as median cell size [interquartile
range, IQR] or as median [IQR] of the proportion of titan cells in a given condition for H99 or
as a ratio compared to the proportion of titan cells obtained with the H99O in experiments
involving other strains (clinical isolates, other H99 strains and mutants). In specific experi-
ments, 104 cells/mL were incubated in 100 well plate (Fischer Scientific) and incubated at 30˚C
with agitation in the Bioscreen apparatus (Fischer Scientific).
In specific experiment using PGAL7 inducible mutants in H99, MM with galactose at 15mM
(galactose MM) was used in parallel to MM containing glucose.
Capsule size analysis
Yeasts were observed after India ink staining and capsule thickness was determined as the size
of the thickness in pixel of the white area surrounding the cell wall imaged with an Olympus
AX 70 microscope and analyzed using the ImageJ software available at https://imagej.nih.gov/
ij/ and the Multi_measures plugin.
Chitin content and capsule structure quantification
Multispectral flow cytometry was used to quantify chitin content after calcofluor white stain-
ing (CFW, fluorescent brightener 28, 0.0001 μg/mL CFW in PBS) and capsule structure after
immunostaining of three anti-capsular antibodies (E1 IgG1 monoclonal antibody [50], both
2D10 [29] and 13F1 [29] IgM monoclonal antibody 30 m at 10 μg/mL) and then incubation
with FITC coupled anti-IgG or -IgM secondary antibodies (15 m at 1:1000 concentration in
PBS). The antibody 18B7 has not been used for this specific experiment because it produces
aggregation that prevented ImagestreamX testing. Pictures were taken in flow and analyzed
using various existing algorithms. We used ImageStreamX with the INSPIRE software (Amnis
Corporation). Cell suspensions were adjusted to 107 in 200 μL and 10,000 cells were recorded
at 40-fold magnification in 3 different channels including the bright field channel (BF) and 2
fluorescence channels (channel 1: 430-505nm [CALCO]; channel 2: 470-560nm [Anticapsular
antibodies]). Data analysis was performed using the IDEAS software (Amnis Corporation)
after fluorescence compensation procedures. The first step consists in the definition of a mask
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that delineates the relevant pixels in each picture. Then, 54 algorithms (calculations made for
each event within a defined mask) are available to analyze size, texture, location, shape or sig-
nal strength. Using basic algorithms, unfocused events, yeasts aggregates were excluded [4].
First titan cells (TC) and typical cells (tC) were selected based on a dot plot Area/Diameter.
We decided to avoid overlap between populations and select well separated population based
on their size after control using the bar added on the picture of the yeasts (see Fig 2A and 2B).
For chitin content, the calcofluor intensity histogram using the Intensity of algorithm in chan-
nel 01 have been generated for TC and tC (see Fig 2C and 2D). For capsule structure, the algo-
rithms dedicated to structure analysis were tested and Modulation and Bright details intensity
R7 algorithms in channel 2 have been found to separate the capsule structure of titan cells
from typical cells populations. For each population of interest, the geometric mean was calcu-
lated using the IDEAS software.
Additional experiments using fluorescence microscopy for chitin content measurement
was performed after calcofluor white staining (CFW, fluorescent brightener 28) adapted from
[42]. Briefly, 107 C. neoformans cells in 10 mL MM were washed once and 500 μL of 3.7%
formaldehyde in PBS was added. Cells were incubated at room temperature for 30–40 m,
inverting the tube every 5 m. Samples were washed twice in PBS, cell concentration was
adjusted to 106 cell/mL. The supernatant was removed and 1 mL of 0.0001 μg/mL CFW in PBS
was added, and incubated 5 m at 25˚C. Cells were then washed twice in PBS. Results were
expressed as median [IQR] of the mean fluorescence intensity/pixel/cell after picture analysis
as described below.
Capsule immunofluorescence and melanization analysis
Capsule immunofluorescence (IF) of titan cells was done by incubating approximately 5x106
cells/mL with 10μg/mL of murine-derived monoclonal antibodies to the cryptococcal capsule
(IgG1 18B7, IgG1 E1, IgM 12A1, IgM 2D10 [29,50] in blocking solution (1% bovine serum
albumin in PBS). Cells and mAb mixtures were done in 1.5 mL microcentrifuge tubes at 37˚C
for 1 h under continuous mixing. Next, cells were washed three times with PBS by centrifuga-
tion (5,000 rpm for 5 m at room temperature) and incubated for 1 h at 37˚C with 5 μg/mL
fluorescently labelled secondary-mAbs, goat anti-mouse IgG1-FITCs or IgM-TRITCs (South-
ern Biotech) in blocking solution and 1 μg/mL of Uvitex2b (Polysciences, Warrington, PA)
solution to visualize the fungal cell wall. Cells were washed three times with PBS by centrifuga-
tion, mounted in glass coverslips and imaged with an Olympus AX 70 microscope equipped
with blue, green and red fluorescent filters using 40x and/or oil immersion 100x objectives.
Capsule immunofluorescence of titan cells preparations performed in two independent experi-
ments gave consistent results.
Titan cells melanization was induced following step 3. Cells were washed once with mini-
mal medium, suspended in 1mL of minimal medium supplemented with 1mM of L-DOPA
(Sigma D9628), transferred to a 5mL Erlenmeyer flask (for normal oxygenation) and incu-
bated at 30˚C under continuous mixing at 200 rpm for 3 d. Since melanin is resistant to acid
hydrolysis, a spherical melanin “ghost” remains following incubation of black cells with 12N
HCl for 1 h at 100˚C (a reduced and modified version of the procedure in [62]. Acid-resistant
melanin “ghosts” were washed three times in PBS by centrifugation and visualized using light
microscopy.
Melanization was measured using imageJ in Icy software by manually circling each cell and
measuring the mean gray intensity / pixel /cell. Blackness was calculated as the maximum
mean grey intensity minus the mean grey intensity / pixel /cell. Increasing melanin content
will result in higher blackness.
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N-acetylglucosamine quantification
H99 cells were grown in MM for 48 h in vitro. Cells were centrifuged 2 m at 14,000 rpm and
were then washed twice with sterile water. These cells were exposed to γ-radiation to remove
layers of the capsule polysaccharide [13, 20]. Cells resuspended in sterile water were trans-
ferred to a 24-well flat-bottom plate and irradiated for 45 m: dose 560 Gy (56,000 rad).Titan
cells and tyical cells were separated [20]. Washed irradiated cells were filtered using CellMicro-
Sieves (BioDesign Inc. of New York, Carmel, NY) with a 10 μm pore size. The CellMicroSieves
were rinsed with PBS to remove typical cells from the filter. To recover the titan cells popula-
tion, the CellMicroSieves were inverted and the membrane was washed with PBS. The TCs
population was concentrated by centrifugation at 12,000 g for 1 m. To recover the typical cells
population, the filter flow-through was concentrated by centrifugation at 12,000 g for 1 m.
Cellular chitin quantification was adapted from [20, 42, 63]. Purified in vitro titan cells and
typical cells were collected by centrifugation at 14,000 rpm for 2 m and the media were
removed. Dry weights were measured following 2–3 d of evaporation at 37˚C. Dried pellets
were extracted with 1 mL 6% KOH at 80˚C for 90 m. Samples were centrifuged at 14,000 rpm
for 20 m. Each pellet was suspended in 1 mL PBS and spun again. Each pellet was suspended
in 0.2 mL of McIlvaine’s Buffer (0.2 M Na2HPO4, 0.1 M citric acid, pH 6.0). Five μL of purified
Streptomyces griseus chitinase (5 mg/mL in PBS) was added to hydrolyze chitin to Gluc-NAc
and incubated for 3 d at 37˚C. Chitinase-treated samples were spun at 14,000 rpm for 1 m,
each 10 μL of sample supernatant was combined with 10 μL 0.27 M sodium borate, pH 9.0.
Samples were heated to 99.9˚C for 10 m. Upon cooling to room temperature, 100 μl of DMAB
solution (Ehrlich’s reagent, 10 g p-dimethylaminobenzaldehyde in 12.5 mL concentrated HCl,
and 87.5 mL glacial acetic acid) was added, followed by 20 m incubation at 37˚C. Hundred μL
was transferred to 96-well plates, and absorbance at 585 nm was recorded. Standard curves
were prepared from stocks of 0.2 to 2.0 mM of Gluc-NAc (Sigma, Saint Louis, Missouri, USA).
The amount of Gluc-NAc was calculated as mmol/g cells (dry weight). Results are expressed as
median [IQR].
DNA content measurement
A 96-well microtiter plate was filled with 200 μL of a 106/mL cell suspension in PBS and centri-
fuged 5 m at 4000 rpm. The pellet was suspended in 150 μL of ethanol 70% and incubated in
the dark 1 h at 4˚C. After discarding the supernatant, a 50 μL mix composed of 44 μL NS
(0.01M Tris HCL pH 7.2, 1 mM EDTA, 1mM CaCl2, 0.25 M Sucrose, 2.12 mM MgCl2, 0.1
mM ZnCl2), 5μL RNase A at 10mg/mL and 1.25μL PI at 0.5mg/mL was added in each well as
described [64]. After a 30 m incubation at 30˚C in the dark, the plate was sonicated 1 m and
each sample diluted at 1:40 in 50mM Tris HCl. The fluorescence intensity was measured using
the Guava easyCyte 12HT Benchtop Flow Cytometer (Guava, MERCK, Kenilworth, New Jer-
sey). Selection of singlets by gating allowed (i) determination of PI intensity on channel YelB
(583/26) in FSC/SSChigh (TC) and FSC/SSClow (tC); (ii) determination of the FSC/SSC distri-
bution in PIhigh and PIlow population. FlowJo software v.10 was used to analyze the data. The
graphs of the number of yeasts were normalized to the mode to depict the data in terms of ’%
of max’. The % of max denotes the number of cells in each bin (the numerical ranges for the
parameter on the x axis) divided by the number of cells in the bin that contains the largest
number of cells.
Determination of the ancestry of titan cells by flow cytometry
Knowing that CFW staining does not alter C. neoformans viability and that daughter cells har-
bored lower CFW signal due to partial cell wall transmission from mother to daughter cells
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[4,30], we analyzed cell size and CFW fluorescence intensity of the progenies of titan cells and
typical cells following the in vitro protocol on 106 cells of H99O pre-stained with CFW (chan-
nel BluV 448/50 using Guava).
Dynamic imaging
Budding rates were determined after yeasts (105 cells composed of titan cells and typical cells)
previously incubated using our protocol or in vivo (see below) were directly deposited in a 35
mm sterile culture dish in minimal medium without agitation and incubated at 30˚C. Pictures
were taken every 2 or 5 m by phase microscopy using the Axiovert 200M inverted microscope
with 40x or 20x objectives (Carl Zeiss MicroImaging, NY), used in conjunction with an Axio-
camMR camera.
Cell size evolution over time was assessed for strain AD2-06a by dynamic imaging (Nikon
Biostation). Briefly, 35 mm sterile culture dish (Hi-Q4, Nikon) were coated for 1 m with E1
antibody at 2 mg/L in order to provide anchor for the capsule. Yeasts (105 cells) were added in
1 mL MM and incubated at 32˚C for 18 h. Series of 221 images were taken by phase-contrast
microscopy every 5 m at ×100 magnification. Merging was done using ImageJ software in Icy
Software.
Impact of various factors on titan cells generation
To analyze the various factors that could impact titan cells generation, we modified the various
steps of our in vitro protocol. For step1, stress was produced by 8 subcultures (twice a week for
one month) on agar medium or on agar supplemented with CFW (20mg/L) or with flucona-
zole (32mg/L). For step 2, the pH of MM (normally at 5.5) was set at 4, 7 or 8.5 without buffer-
ing. For step 3, initial cell concentration (from 104 to 107cells/mL) was tested. Hypoxia was
generated physically by closing the cap of the Eppendorf1 tube during 5 d or chemically upon
incubation in MM supplemented with 1 nM CoCl2, cap closed, as already described [65]. The
production of titan cells was also assessed in the presence of various reagents added at step 3:
(1) Qsp1 peptide (NFGAPGGAYPW, [33]) (Biomatik, Cambridge, Canada) was resuspended
at 10mM in water and stored at -80˚C until use at 10 μM final with the scrambled peptide
(AYAPWFGNPG) as a control; (2) pantothenic acid purchased from Sigma (Saint-Louis, Mis-
souri, USA) used at 125 μM; (3) monoclonal anti-capsular antibodies E1 [50] and 18B7 [51]
used at a final concentration of 166 μg/mL in MM [66]; (4) decomplemented fetal calf serum
(FCS, Invitrogen, Carlsbad, CA, USA) at 5% in MM; (5) L-α-Phosphatidylcholine from egg
yolk (Sigma, Saint-Louis, Missouri, USA) was extemporaneously reconstituted at 5 mM in
MM; (6) antifungal drugs (fluconazole and flucytosine) were tested at the concentrations close
to the MIC (2-fold dilutions) with the diluent (DMSO or water) as control. Results are
expressed as median [IQR]. Growth in the presence or in the absence of antifungal drugs was
evaluated by enumeration of yeast cells concentration at step 4 of our protocol using the
Guava cytometer, starting from 106 cells inoculated at step 1.
Production and isolation of titan cells from infected mice
C. neoformans strains were cultured overnight at 30˚C in YPD broth medium (BD, Hercules,
Canada). Yeast cells were collected by centrifugation, washed with phosphate buffered saline
PBS and resuspended in sterile saline. For titan cells analysis in vivo, groups of 6- to 8-week-
old C57BL/6J mice (Jackson Labs, Bar Harbor, Maine) were anesthetized by 5% isofurane
inhalation for 1–5 m, infected intranasally with 2 × 105 cells in a 40 μL volume and sacrificed
at D6. In these experiments, 84% of titan cells were obtained. For mutant screening, groups of
6- to 8-week-old C57BL/6J mice (Jackson Labs, Bar Harbor, Maine) were anesthetized by
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intraperitoneal pentobarbital injection and infected intranasally with 5 × 106 cells in a 50 μL
volume. Infected mice were sacrificed by CO2 inhalation at 3 d post-infection. The lungs were
harvested, homogenized, and then resuspended in 10 mL PBS supplemented with collagenase
(1 mg/mL) [20]. Cell homogenates were incubated for 1 hour at 37˚C with agitation, and
washed several times with double distilled water. The C. neoformans cells were fixed with 3.7%
formaldehyde for 40 m, washed 3 times with sterile PBS, and then resuspended in sterile PBS.
The proportion of titan cells and typical cells were determined by microscopy. Data presented
were from 3 mice per strain, except for strains sgf29Δ in H99O, H99S that had 2 mice per
strain.
Mutant generation
We PCR amplified the PKR1 and TSP2 genes using the primer KN99α DNA as substrate and
the following primers (PKR1F: AAGCTTggaatgaagatgaaattagtacgtg; PKR1R: ACTAGTgtccat-
cattgctgtaacttggttg; TSP2F: GAGCTCaactccgatgatcatggactcgg; TSP2R: GAGCTCtgcccaagagac-
tagagtgtaacc). The 2559 bp TSP2 and the 2000 bp PKR1 amplicons were cloned in the pGEMT
easy vector (Clontech) and sequenced. The pNE609 and pNE610 plasmids were then con-
structed by cloning the PKR1 and TSP2 DNA fragments into the pSDMA57 plasmid [67]
using the SpeI/HindIII and SacI cloning sites, respectively.
To create transformants, the plasmids pSDMA57 containing PKR1 amplicon was linearized
with BaeI and biolistically transformed into AD2-06a and Bt156 clinical strains. To comple-
ment the tsp2Δmutant, pSDMA57 plasmid containing TSP2 gene was linearized with BaeI
and biolistically transformed into the tsp2Δmutant strain. All transformants were selected on
YPD supplemented with neomycin. Genomic DNA was purified from the transformants and
PCR was used to check the presence of PKR1 and TSP2 genes in the transformed strains. PCR
reactions contained 1 μl gDNA, 2.5 μl of each of the 10 mM primer stocks (PKR1 forward,
PKR1 reverse, TSP2 forward, TSP2 reverse) 5 μl Taq buffer, 4 μl dNTPs, 0.25 μl ExTaq poly-
merase (New England Biolabs, USA) and 34.75 μl sterile water. The cycling parameters were
35 cycles of 94˚C for 20 seconds, 54˚C for 20 seconds and 72˚C for 90 seconds. Products were
visualized using electrophoresis with 0.8% TAE agarose gel. To differentiate between random
integration, single insertion, and tandem insertion into the safe haven, we performed a similar
PCR as above using primers UQ1768, UQ2962, UQ2963, and UQ3348 as previously described
[67].
DNA sequencing, variant identification, and bioinformatic analysis
Genomic DNA was adapted for Illumina sequencing using Nextera reagents. Libraries were
sequenced on an Illumina HiSeq to generate 101 base reads. most data was previously described
[39,68] and one additional isolate was newly sequenced for this study (AD2-07) (NCBI SRA
accession SRR5989089). Reads were aligned to the C. neoformans H99 assembly (GenBank
accession GCA_000149245.2 [34] using BWA-MEM version 0.7.12 [69]. Variants were then
identified using GATK version 3.4 [70], where indels were locally realigned, haplotypeCaller
was invoked in GVCF mode with ploidy = 1, and genotypeGVCFs was used to predict variants
in each strain. All VCFs were then combined and sites were filtered using variantFiltration with
QD< 2.0, FS> 60.0, and MQ< 40.0. Individual genotypes were then filtered if the minimum
genotype quality< 50, percent alternate allele< 0.8, or depth< 5. Variants were then function-
ally annotated with SnpEff version 4.2 [71]. For phylogenetic analysis, the 535,968 sites with an
unambiguous SNP in at least one isolate and with ambiguity in at most 10% of isolates were
concatenated; insertions or deletions at these sites were treated as ambiguous to maintain the
alignment. Phylogenetic trees were estimated using RAxML version 8.2.4 [72] under the
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GTRCAT model in rapid bootstrapping mode. For determination of Pkr1 architecture
domains, the INTERPRO tool was used (http://www.ebi.ac.uk/interpro/protein/J9VH50).
Pictures analysis using Icy software and statistical analysis
To increase the number of events analyzed in each condition tested/each parameter analyzed
(cell size, capsule size and chitin content), pictures of 3–5 fields were taken with an AxioCam
MRm camera (Carl Zeiss, Oberkochen) at x40 on interferential contrast microscope (DMLB2
microscope; Leica, Oberkochen). Image were then analyzed (for cell size and chitin content)
using Icy software v.1.9.2.1.[73] (icy.bioimageanalysis.org) and a specific plugin (HK-Means
plugin (http://icy.bioimageanalysis.org/plugin/HK-Means) that allows analysis of multiple
structures from a bright field. Preliminary experiments were done to compare results obtained
with Icy to "manual" measurements by analyzing about 200 cells on the same pictures for 3
independent experiments. In subsequent experiments, results were pooled for a given condi-
tion from 2 to 3 independent experiments after good reproducibility was assessed.
Statistical analysis was performed with STATA1 software (College Station, Texas, v13.0).
To validate the cell size determination using the Icy software, the intraclass correlation coeffi-
cient was calculated. The ability of the automated method to classify the C. neoformans cells as
titan cells or typical cells compared to visual measurement was evaluated using the Kappa test
[74]. To compare titan cells generation in the various conditions, non-parametric tests were
performed using the Kruskal-Wallis test for multiple comparisons or Mann Whitney test as
required. GraphPad Prism software (v.6) was used to generate graphs.
Data access
All sequence data from this study have been submitted to NCBI BioProject (https://www.ncbi.
nlm.nih.gov/bioproject) under accession number PRJNA174567.
The AD2-07 sequence is available in the NCBI SRA under the accession number
SRR5989089
(https://www.ncbi.nlm.nih.gov/sra/SRR5989089/))
Supporting information
S1 Fig. In vitro protocol of titan cells generation. The protocol followed four steps: (1) C.
neoformans H99O from a frozen stock culture at -80˚C was cultured on Sabouraud agar for
2–5 d; (2) Approximately 107 yeasts were then suspended in 10mL of liquid Yeast Peptone dex-
trose (YPD) and incubated under agitation (150 rpm) at 30˚C for 22 h (stationary phase); (3) 1
mL of the culture was then washed twice in minimal medium (MM), then 106 yeasts were
resuspended in 1mL of minimal medium (MM) pH5.5, in a 1.5 mL Eppendorf tube and incu-
bated at 800 rpm for up to 120 h using an Eppendorf thermomixer; (4) A mixture of typical
cells and of titan cells was ready for analysis.
(TIFF)
S2 Fig. Among yeasts recovered at the end of the in vitro protocol, those with the highest
DNA content have the biggest cell size. DNA content was analyzed after propidium iodide
(PI) staining of yeast cells obtained at the end of our protocol (H99O induced), in a control
haploid strain (H99O cultured in Sabouraud agar, H99O-sab) and in a control diploid strain
(AD7-77 cultured in Sabouraud agar). Part of the population of H99O-induced had a higher
PI (blue arrow) fluorescence intensity than the haploid control (upper panel). Gating on the PI
intensity showed that the increase in the PI fluorescence intensity from <20K to>40K corre-
sponded to increase in cell size (FSC) (red arrows) compared to the diploid (AD7-77) and
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haploid (H99O Sab) control (lower panel).
(TIFF)
S3 Fig. The FSChigh/CFWhigh population of yeasts correspond to titan cells (TC). Cells
obtained using our in vitro protocol were stained with CFW and sorted by flow cytometry
according to size (FSC) and CFW fluorescence intensity (left panel). Sorted yeasts were
observed using bright field and fluorescence microscopy (right panel) (bar = 10μm). Typical
cells (tC) were FSClow/CFWlow.
(TIFF)
S4 Fig. Chitin characterization and melanization of titan cells. (A) Chitin was denser in
titan cells (TC) than in typical cells (tC) according to CFW fluorescence intensity/pixel/cell
measured by Icy software after CFW staining (0.01 μg/mL) at step 4 of the protocol
(p<0.0001). Dots represent individual cells, and boxes median and IQR for 400 cells each
(p<0.001, pooled measurements from 3 independent experiments). (B) N-acetylglucosamine
(GlcNAc), the monomer component of chitin, was increased in titan cells (TC) compared to
typical cells (tC) in vitro (left panel) and in vivo (right panel) as measured by a biochemical
method after gamma-irradiation of the yeasts to remove the capsule, allowing a better separa-
tion of titan cells and typical cells. Each dot represents result from independent experiments
(n = 7). Results are presented as median and IQR (p<0.001). (C) Comparing the blackness of
the cell body of titan cells (TC) and typical cells (tC) upon melanization conditions showed
that titan cells contained more melanin than typical cells. (Bar = 10μm). (D) Melanization was
more important in titan cells (TC) than typical cells (tC) (p<0.0001) based on the calculation
of the max—mean grey value/pixel of each melanin ghost measured (n = 19 for titan cells and
n = 531 for typical cells) using the ImageJ in Icy software. Each dot represents an individual
cells and boxes median and IQR.
(TIFF)
S5 Fig. Capsule structure of titan cells. (A) Using multispectral flow cytometry and capsule
staining using anticapsular monoclonal antibodies (mAb), we discriminated the distribution
of titan cells and typical cells with almost no overlap between both population with 2D10 mAb
in vitro and in vivo, based on the algorithm modulation and Bright details intensity R7. Over-
lap in the staining characteristics of titan cells and typical cells were observed for E1 (IgG1)
and 13F1 (IgM) antibodies. (B) Immunofluorescence staining with the anti-capsular mAbs
2D10, 12A1, 18B7, and E1 does not uncover major differences in capsular structures between
titan cells (white arrows) and typical cells (black arrows). Each panel correspond to the same
cells observed after staining with (a) India ink; (b) calcofluor white; (c) one of the Mabs; (d)
merge of c and d. (bar = 10μm).
(TIFF)
S6 Fig. Growth is maintained in the presence of antifungals after our protocol. 106 cell/mL
were inoculated at step 1 of our protocol, then cell growth was evaluated by enumerating cell
concentration obtained at step 4 of our protocol using Guava flow cytometer for cell counting.
(A) Compared to control, fluconazole did not modify cell growth in MM whereas (B) flucyto-
sine (5FC) reduced it, when used at concentration near the minimum inhibitory concentration
(MIC) for 5 d (p<0.0001 compared to unexposed control). The fluconazole and flucytosine
MICs for H99O were 8 mg/L and 4 mg/L, respectively. Experiments were done in triplicates
(bars represent mean ± SD). (C) Cycloheximide also reduced cell growth at 0.0001 and inhibit
cell growth at 0.001 mg/mL (p<0.0001 compared to unexposed control).
(TIFF)
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S7 Fig. Test of iterative subcultures affect titan cells formation with or without the pres-
ence of active molecules (CFW or fluconazole). Step 1 was modified by sub-culturing H99O
8 times over one month on Sabouraud agar alone (Sub8), or supplemented with 20mg/L CFW
(Sub8+CFW) or with 32mg/L fluconazole (Sub8+FLC). Compared to initial culture (0Sub), 8
sub-cultures (8Sub) decreased significantly the cell size ( p<0.0001, vs 0Sub control). In
addition, iterative subcultures on CFW and FLC decreased and increased significantly the cell
size compared to the 8Sub control, respectively. Median and IQR are shown in black for each
condition ( p<0.0001 vs 8Sub control). The numbers above each condition represent the pro-
portion of titan cells observed. The experiments were performed in triplicate and pooled
(mean cell counted ± SD = 2455±913).
(TIFF)
S8 Fig. Titan cells generation is dependent on various genes in vitro and in vivo. (A) Strains
from the H99 lineage harbored variable abilities to generate titan cells with H99 being the
main producer in in vitro and H99O and KN99α in vivo ((B)) compared to the other
H99strains (S, L, W, CMO18). (C) The sgf29Δand lmp1Δmutant strains show a decrease in
titan cells generation in various H99 backgrounds in vitro and (D) in vivo compared to H99O.
(E) Rim101 and PKA pathway is required for titan cells generation in vitro in H99. Each exper-
iment was done in triplicates. Results are presented as stacked bar of the proportion of titan
cells (titan cells) and regulars cells (typical cells),  p<0.0001 vs control H99O.
(TIFF)
S9 Fig. Titan cells generation is dependent on various genes and requires signaling through
the Gpr/PKA/Rim101 pathway in vivo. (A) The different H99 strains harbored variable abili-
ties to produce titan cells compared to H99O (grey bar). KN99α in vivo has similar results than
H99O in vivo. (B) Sgf29Δand lmp1Δ deletion mutants show a decrease in titan cells generation
in various H99 backgrounds in vivo compared to H99O. The complementation of the genes
with the corresponding mutant rescued the phenotype observed for the parental strain in vivo.
(TIFF)
S10 Fig. USV101 and SRE1 deletion influenced titan cells formation. (A) usv101Δ is a
repressor of titan cells formation. (B) The sre1Δmutant strain decreased titan cells formation
compared to the parental strain KN99α. The ratio to KN99α, used as a calibrator in each
experiment, was calculated for each strain and results expressed as mean ±SD. To compare the
experimental conditions to KN99α, Khi2 analysis was performed (p<0.0001).
(TIFF)
S11 Fig. Chr9 ploidy does not influence titan cells generation. A panel of 7 clinical isolates
with partial Chromosome 9 duplication (left panel) was tested for its ability to generate titan
cells. Only H99O and AD2-06a exhibited increased cell sizes (middle panel). The proportion
of titan cells was 67.9% (431/667) for AD2-06a, 32.1% (429/1339) for H99O, and 4.2% (51/
1227), for Ug2459 (Khi2 compared to H99O, p<0.0001) with the ratio of the proportion of
titan cells to that produced in H99O shown in the right panel.
(TIFF)
S12 Fig. PKR1 mutations influence median cell size. Strains with Pkr1 loss of function muta-
tion showed a variable ability to produce titan cells depending on the resulting truncated pro-
teins. The clinical isolate AD2-07 which did not harbor the PKR1mutation was recovered
from the CSF of an HIV-positive patient on d 13 of amphotericin B treatment while AD2-06a
was recovered from its initial CSF. The median cell size (5.9 μm [5.2–6.6]) was significantly
decreased in AD2-07 and increased in AD2-06a (8.5 μm [7.0–13.0]) compared to H99O
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(7.7 μm [6.6–9.2]) (p<0.0001). Except Bt156 (median of 7.7 μm [6.4–9.4]), the others strains
had a significantly decreased median size compared to H99O (p<0.0001), 6.9 μm [6.0–7.8] for
8–1 strain; 6.5 μm [5.8–7.1] for Bt77, 6.4 μm [5.7–7.2] for Bt117; and 5.4 μm [4.7–6.1] for
Ug2462. Experiments were done in triplicate and pooled.
(TIFF)
S13 Fig. Non-synonymous mutation in USV101 enhances titan cells generation based on
clinical isolates analysis. Bt88 harbored a truncated Usv101 protein due to a frameshift muta-
tion. The titan cells generation is negative in Bt31, Bt40, Bt89, Bt105 and Bt133 and increased
for Bt88 with a ratio at 0.6±0.4 and a proportion of titan cells of 21.6% (423/1958) compared to
H99O 38.5% (729/1890). Experiments were done in triplicate and pooled.
(TIFF)
S1 Movie. Time lapse imaging of titan cells and typical cells generated in vitro (after 5 d)
allowed to grow. Titan cells produced normal sized daughter cells upon incubation in fresh
MM (at 30˚C, one picture every 2min during 24 h).
(M4V)
S2 Movie. Time lapse imaging of titan cells and typical cells generated in vivo (6 d post
infection, intranasal route) allowed to grow. Titan cells produced normal sized daughter
cells upon incubation in fresh MM (at 30˚C, one picture every 5 m during 24 h at ×400 magni-
fication using transmitted light (white bar = 10 μm, NC = typical cells).
(M4V)
S3 Movie. Time lapse imaging showing mothers cells increasing in time allowing titan cells
generation first produced between 8 and 12 h of incubation. Dynamic imaging of yeasts
from the AD2-06a C. neoformans clinical isolate using the Nikon Biostation IM. Yeasts were
seeded in MM on a culture dish that was previously coated with E1 at 2 mg/L. Images were
taken every 5 m for 24 h at ×100 magnification using transmitted light (white bar = 10 μm).
(AVI)
S1 Table. Gene disrupted in AD2-06a but not in closely related isolated AD3-55a or AD3-
41a.
(DOCX)
S2 Table. Clinical isolates with chromosome 9 ploidy variation.
(DOCX)
S3 Table. Strains harboring Pkr1 loss-of-function mutations used in this study.
(DOCX)
S4 Table. Strains used in this study.
(DOCX)
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